Purpose: Despite a lack of consensus concerning the etiology of interstitial cystitis (IC) the loss of impermeability and other abnormalities of the urothelium are features of the disease. In this study the distribution of proteins involved with epithelial adhesion, cellular differentiation and bladder impermeability in urothelial biopsies were explored by the immunohistochemical assessment of E-cadherin, ZO-1, uroplakin and chondroitin sulfate.
Interstitial cystitis (IC) is a poorly understood disease that affects women and men to a lesser extent, and significantly impairs quality of life. Epidemiological studies have estimated the prevalence of the disease to be greater than 1 million individuals affected in the United States. 1, 2 Although the definition and the diagnostic criteria have evolved during the years as evidenced by the National Institutes of Health consensus conference of 1987 and the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases funded Interstitial Cystitis Data Base project of 1993 to 1997, 3, 4 IC remains a diagnosis of exclusion.
Although there is a lack of consensus concerning the etiology of IC, numerous lines of evidence suggest that loss of impermeability and other abnormalities in the urothelium are features of the disease. [5] [6] [7] [8] [9] [10] In this study we examined the distribution of the proteins involved with epithelial adhesion, cellular differentiation and bladder impermeability in urothelial biopsies from patients with well characterized IC and controls. There were certain markers examined and rationales for selection. E-cadherin has a crucial role in urothelial differentiation. 11 ZO-1 forms tight junctions that contribute to the impermeability of the bladder urothelium. 12, 13 Uroplakin, the major hydrophobic urothelial protein found on the surface of umbrella cells, also contributes to bladder impermeability. 13, 14 Chondroitin sulfate is a component of the so-called glycosaminoglycan GAG layer, which has been implicated as having a role in maintaining bladder impermeability 5 and has been shown previously to be decreased in IC. 15 
MATERIALS AND METHODS
Patient population. Informed consent for this research project was obtained from each patient prior to specimen collection. Specimens were collected from 27 patients (21 females and 6 males) meeting the current relaxed criteria for patient entrance into clinical studies of IC, as established by the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, 1 including moderate to severe disease symptoms greater than 6 months in duration, an average age of 38.2 years (range 23 to 63) and undergoing therapeutic cystoscopy and hydrodistention. Seven female patients with an average age of 46.1 years (range 21 to 66) who were known to be free of bladder mucosal disease and urinary tract infection, and were undergoing a bladder suspension procedure for stress urinary incontinence underwent bladder biopsy and served as controls.
Specimen collection. cup rigid biopsy forceps of the posterior bladder wall through a 22Fr rigid cystoscope. Control samples were obtained in similar fashion from patients undergoing suspension for stress incontinence without hydrodistention at 90 cm for 5 minutes. All samples were immediately fixed in formalin and subsequently mounted in paraffin.
Immunohistochemical analysis of marker proteins. A 5 m section was cut from each specimen, dewaxed with a graded xylene and ethanol series, and rehydrated with a graded ethanol water series. Immunohistochemical labeling for ZO-1 tight junction protein, uroplakin, chondroitin sulfate and E-cadherin was performed. The primary mouse antibody for ZO-1 was used at 1:100 dilution. This mouse monoclonal antibody, designated ZO1-1A12 (Zymed Laboratories, South San Francisco, California), is an IgG 1 -isotype. The mouse monoclonal antibody against uroplakin was used at 1:1,000 dilution. Chondroitin sulfate analysis was performed with 2B6 mouse monoclonal antibody (ICN Biochemicals, Costa Mesa, California) against the stub resulting from chondroitinase (Proteus vulgaris) avidin-biotin-peroxidase digestion of sections. It was used at a dilution of 1:50. Analysis of E-cadherin protein expression was performed using clone 4A2 C7 mouse monoclonal IgG 1 -(Zymed Laboratories) at a dilution of 1:50.
Tissue sections were incubated with primary antibody for 30 minutes at 37C using an automated staining process after blocking nonspecific binding with Automation Buffer detergent and protein containing buffer (BioGenex, San Ramon, California). The appropriate antibody dilution was determined experimentally by titration. For chondroitin sulfate analysis sections were predigested with 10 mU chondroitinase for 15 minutes. This assay was optimized to display chondroitin sulfate expression in the urothelium by the titration of incubation time with chondroitinase. A common secondary system of goat antimouse labeled with horseradish peroxidase (1:100 dilution) and 3-amino-9-ethyl carbazol chromogen was used for all immunohistochemical labeling. Positive assay controls consisted of normal kidney and normal bladder. An isotype controlled unrelated antibody served as a negative control. Images of stained sections were captured using a Microphot FXA microscope (Nikon Corp., Tokyo, Japan) equipped with a Color Chilled 3 charge coupled device camera (Hammamatsu Corp., Bridgewater, New Jersey).
Tissue sections were scored for the distribution of each marker and for urothelial morphology. The scoring system combined previously published information on the distribution of these markers in the bladder 10 -13, 15-17 as well as our observations of the specimens. The figure shows examples of normal and abnormal patterns of each marker. We present the details of the scoring system.
Morphology/polarity was scored as 0 -urothelium 1 to 2 cells thick with all cells the same size and the umbrella cell layer absent, 1-urothelium 3 to 5 cells thick with all cells the same size and the umbrella cell layer absent, 2-some polarization evident with some stratification of cell size and umbrella cells spotty or urothelium thin (about 3 cells thick), and 3-urothelium polarized with respect to cell size with umbrella cells covering most of the urothelium uniformly and the urothelium generally 5 cells or more thick.
Chondroitin sulfate was scored as normal-dense luminal staining with decreasing expression from luminal to apical layers and abnormal-absent strong layer on the luminal surface or a uniform distribution throughout the urothelial layer.
ZO-1 was scored as normal-uniformly distributed throughout the urothelium but possibly more intense under the umbrella cell layer with minimal expression in the cytoplasm with each cell outlined by the marker, and abnormalpatchy, sometimes absent, or expressed in cytoplasm and not organized on cell surfaces.
Uroplakin was scored as normal-found only on the luminal layer, where it was densely distributed, and abnormalweak on the luminal layer or distributed throughout the urothelium.
E-cadherin was scored as normal-concentrated in the umbrella cell layer or immediate underlying the cell layer and abnormal-densely expressed throughout the urothelium.
Statistical analyses. The significance of differences between controls and patients with IC was tested with Fisher's exact test using 2 ϫ 2 contingency tables. Pearson's nonparametric correlation analysis was used to test for relationships among markers. We used Prism 3 (GraphPad Software, San Diego, California).
RESULTS
Normal bladders demonstrated urothelium that usually was 5 cells or more thick and showed a gradation in cell size from the basal to luminal layer with a distinct umbrella cell layer on the luminal surface. In contrast, IC bladders tended to have a thinner urothelium, often lacking a distinct umbrella cell layer with cells that failed to increase in size from the basal to luminal surfaces. In some IC samples the whole urothelium was only 1 or 2 cells thick. The figure shows representative photographs of the normal and abnormal distribution of the 4 markers.
Chondroitin sulfate was expressed in normal control spec- 
the basal layer. The stroma generally stained lightly due to extensive chondroitin sulfate proteoglycan in the connective tissue. In many abnormal samples the marker was not localized to the umbrella cell layer and it was uniformly distributed throughout the urothelium. Occasionally a patchy distribution was noted but complete absence was not observed.
ZO-1, which is the zona occludens protein responsible for tight junctions, was distributed throughout the urothelium in normal samples. Each cell was outlined with the label, which tended to be most intense in the first layer of cells beneath the umbrella cell layer. IC bladders generally showed a heterogeneous staining distribution. Often ZO-1 was found in cytoplasm but not organized into tight junction structures outlining cells or it was absent. The absence of ZO-1 was often expressed in a patchy pattern.
Uroplakin was normally distributed in a dense layer concentrated on the luminal surface of the umbrella cells with no expression noted elsewhere in the urothelium. In abnormal samples it was often expressed throughout the urothelium regardless of the thickness of the urothelium or the presence of umbrella cells. In areas showing a thinned urothelium of 2 or 3 cells and lacking umbrella cells the protein was expressed by most cells. In 1 control bladder an area of abnormality was observed that grew as successive sections were cut from the block. The urothelium abruptly thinned from an entirely normal pattern to one that was 2 or 3 cells thick at most, and in which uroplakin was distributed uniformly throughout the cell layer. Because the normal area was shrunken in the section used to measure uroplakin, the section was scored as abnormal.
E-cadherin was expressed most strongly in normal cells in the umbrella cell layer. Like ZO-1, in normal specimens the marker was expressed at the cell periphery and it outlined the cells. In IC samples E-cadherin was generally over expressed, showed no polarity of distribution and was often seen in the cytoplasm.
Using the scoring system derived from these observations all specimens were scored with results according to the sample and marker (tables 1 and 2). Only 3 of IC samples appeared completely normal, 24 of 27 showed at least 1 abnormality and in 6 of 27 all 4 markers were abnormal. Correlation analysis identified some significant relation-ships among the markers in IC specimens. The morphology/polarity score significantly correlated with ZO-1 (Pearson r ϭ 0.3935, p ϭ 0.0423) and chondroitin sulfate (Pearson r ϭ 0.7079, p Ͻ0.0001) expression. Chondroitin sulfate and ZO-1 showed a high correlation to each other (Pearson r ϭ 0.5587, p ϭ 0.0025). Uroplakin expression was independent of all other markers with no correlation exceeding 0.2 (p Ͼ0.3283). E-cadherin expression was also independent of all other markers with no correlation exceeding 0.35 (p ϭ 0.0707 vs morphology/polarity).
DISCUSSION
Despite several decades of intensive research IC remains a poorly understood bladder disorder. The symptoms classically associated with IC are frequency, urgency, nocturia and suprapubic pain in the absence of urinary tract infection. 3 Additional features used to diagnoses of IC are decreased awake bladder capacity and bladder submucosal petechial hemorrhages (glomerulations) after bladder hydrodistention. 1, 4 Some exclusion criteria are detrusor instability, age younger than 18 years, fewer than 9 months since symptom onset and the ability to explain symptoms with other etiologies, such as infection, cancer, radiation and calculi. To our knowledge IC remains a diagnosis of exclusion to date.
Although no consensus has been achieved, the previously explored etiologies of IC include increased bladder epithelial permeability, mast cell activation, release of inflammatory mediators, subclinical infection, neuropathic changes, toxic compounds in the urine and impaired bladder vascular supply. 18 A major function of bladder epithelium is to provide an impermeable barrier to urinary solutes, such as ammonia, urea, potassium and creatinine, that are being excreted in the urine. It has been suggested that IC symptoms may arise from increased permeability of the bladder epithelium. 8, 19 The urothelium has several levels of defenses against low and high molecular weight solutes, including the dense layer of glycosaminoglycans and glycoproteins on the luminal layer, tight junctions, hydrophobic uroplakin plaques and active ion pumps. 5 In this study we noted objective evidence for widespread abnormalities in the expression of proteins associated with urothelial defenses and differentiation. Only 3 of 27 biopsy specimens were normal for all 4 markers. Only 1 control specimen showed any abnormal findings that were associated with a focal defect, as manifested by a thinned urothelium. In single biopsies 67% of IC cases over expressed E-cadherin and 56% expressed abnormal chondroitin sulfate. Although the conclusion that patients with IC show a deficit of chondroitin sulfate remains the same, chondroitin sulfate labeling is apparently inconsistent with previous reports from our laboratories, 5, 15 in which connective tissue staining was more intense, and 81% of patients with IC and 42% of controls showed little or no labeling in the urothelium. The difference represents an assay artifact. The chondroitinase enzyme used to liberate the stub oligosaccharide that reacts with the antibody apparently also contains weak glycosidase activity. In previous studies the assay was standardized against the abundant but apparently more difficult to digest chondroitin sulfate in the stroma. As a consequence, over digestion eliminated the reactive stub, starting with the more available chondroitin sulfate in the urothelium. In the current study the assay was carefully optimized to represent more faithfully the actual concentrations of chondroitin sulfate present in the urothelium.
Previous studies of the sequence of expression of uroplakin, E-cadherin and ZO-1 showed that the polarized pattern of expression seen in the normal samples develops in a definite sequence. 11 The findings currently reported strongly suggest abnormal differentiation in the IC bladder. Moreover, the labeling of chondroitin sulfate and uroplakin in areas of thin urothelium suggests a lack of umbrella cells and polarization, and the fact that the frequent denuded areas 10, 16 are not artifacts of preparation or biopsy. If the umbrella cell layer were stripped off as an artifact, the lower cells would not be expected to be labeled because they were not labeled in normal specimens. It is a crucial point because there was no medical indication for distention in controls. The over expression of E-cadherin confirms previously reported findings at the gene transcription level. 20 Because E-cadherin expression inhibits proliferation, the findings suggest that the thinned urothelium seen by us and others in IC cases is due to failure of the layer to follow the normal course of proliferation of multiple layers, followed by terminal differentiation.
An interesting feature of our data is the heterogeneity of the distribution of abnormal findings in patients with IC of whom 3 were completely normal and 6 showed only a single abnormality. The results were based only on a single biopsy and to our knowledge it is unknown whether IC alters urothelial differentiation of the whole bladder, particularly in less severely affected patients. Because the stratification of IC cases is highly subjective, a large sample size, possibly with multiple biopsies, would be needed to assess accurately whether the number of abnormal findings correlates with disease severity.
The markers fell statistically into 3 groups, namely chondroitin sulfate/ZO-1/morphology, E-cadherin and uroplakin. The correlation between chondroitin sulfate and ZO-1, and with morphology suggests that these 2 biomarkers may be related to the same functional system and they are regulated by differentiation related processes. Each has been implicated separately in barrier function, 5, 17 and the finding of a strong correlation supports that they function together in maintaining the impermeability of the bladder surface. The disruption of ZO-1 was previously reported in feline IC 17 but we found no reports of disruption in human disease. Our findings of a similar lack of expression of ZO-1 protein suggest that the human and feline diseases express at least these features in common. Interestingly the lack of tight junctions in the cat failed to disrupt permeability entirely, suggesting that other molecules may compensate for damaged barrier function. To our knowledge the expression of chondroitin sulfate in feline IC has not been reported. It is possible that elevated E-cadherin may represent an adaptation to increased bladder permeability. The heterogeneity of findings suggests that abnormalities in these 3 groups may emerge independently and could indicate that abnormal differentiation is secondary to disease or different etiologies can produce similar symptoms.
CONCLUSIONS
The abnormal expression of biomarkers for bladder impermeability and differentiation was noted in biopsy specimens from patients with IC compared to normal controls. Only 3 of 27 biopsy specimens showed normal marker patterns. These data suggest abnormal differentiation in the IC bladder.
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